Boonton, NJ, United States of America

Fu-chin Huang

This inventor holds 1 USPTO granted patent. Top assignee: Usv Pharmaceutical Corporation. Active years: 1987.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fu-chin Huang. Retrieved from https://idiyas.com/inventor/fu-chin-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Fu-chin Huang in Antihypertensive Compounds

Introduction

Fu-chin Huang is a notable inventor based in Boonton, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antihypertensive activity. His work has the potential to impact the treatment of hypertension, a prevalent health issue.

Latest Patents

Fu-chin Huang holds a patent for 1,2,3,4-Tetrahydrophthalazine and hexahydropyridazine compounds. These compounds are characterized by their general formula and their pharmaceutically-acceptable salts. The substituents in these compounds are defined in the patent, highlighting their specific applications in antihypertensive treatments.

Career Highlights

Huang is associated with Usv Pharmaceutical Corporation, where he has been instrumental in advancing pharmaceutical research and development. His expertise in creating innovative compounds has positioned him as a valuable asset in the industry.

Collaborations

Some of his notable coworkers include Howard Jones and Wan-Kit Chan. Their collaborative efforts contribute to the ongoing research and development initiatives at Usv Pharmaceutical Corporation.

Conclusion

Fu-chin Huang's work in developing antihypertensive compounds showcases his innovative spirit and dedication to improving healthcare. His contributions are significant in the pharmaceutical field, and his patent reflects the potential for advancements in hypertension treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…